371 related articles for article (PubMed ID: 29373227)
1. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Tanahashi N; Yamaguchi T; Awano H; Matsuda H
J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
[TBL] [Abstract][Full Text] [Related]
2. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
Yamaguchi T; Awano H; Matsuda H; Tanahashi N;
J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):756-765. PubMed ID: 27887792
[TBL] [Abstract][Full Text] [Related]
3. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
[TBL] [Abstract][Full Text] [Related]
4. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
Tsuruoka A; Atsumi C; Mizukami H; Imai T; Hagiwara Y; Hasegawa Y
J Stroke Cerebrovasc Dis; 2014; 23(10):2894-2899. PubMed ID: 25282183
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
[TBL] [Abstract][Full Text] [Related]
6. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
8. Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100 kg on 3-Month Outcomes in Acute Ischemic Stroke.
Garavaglia J; Sherman J; Yetzer H; Regier M; Smith M
J Stroke Cerebrovasc Dis; 2017 May; 26(5):1041-1046. PubMed ID: 28129994
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry.
Kamouchi M; Sakai H; Kiyohara Y; Minematsu K; Hayashi K; Kitazono T
J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e470-6. PubMed ID: 23800495
[TBL] [Abstract][Full Text] [Related]
10. Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
Momosaki R; Yasunaga H; Kakuda W; Matsui H; Fushimi K; Abo M
Cerebrovasc Dis; 2016; 42(1-2):41-8. PubMed ID: 26986718
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Changes in Leukocytes Levels 24 Hours after Intravenous Thrombolysis With Prognosis in Patients With Acute Ischemic Stroke.
Chen J; Zhang Z; Chen L; Feng X; Hu W; Ge W; Li X; Jin P; Shao B
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2857-2862. PubMed ID: 30064868
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
Takenaka K; Kato M; Yamauti K; Hayashi K
J Stroke Cerebrovasc Dis; 2014; 23(10):2748-2752. PubMed ID: 25307430
[TBL] [Abstract][Full Text] [Related]
13. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
Wada T; Yasunaga H; Inokuchi R; Horiguchi H; Fushimi K; Matsubara T; Nakajima S; Yahagi N
J Neurol Sci; 2014 Oct; 345(1-2):106-11. PubMed ID: 25085762
[TBL] [Abstract][Full Text] [Related]
14. Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
Baba H; Sugimori H; Nanishi E; Nagata H; Lee S; Kuwashiro T; Hashizume M
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):903.e5-8. PubMed ID: 21421331
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Nonagenarians with Acute Ischemic Stroke Treated with Intravenous Thrombolytics.
Behrouz R; Masjuán-Vallejo J; Vera R; Willey JZ; Zedet M; Moulin S; Cordonnier C; Klijn CJM; Kanselaar K; Dirks M; Silver B; Khan M; Azarpazhooh MR; Godoy DA; Roffe C; Paley L; Bray BD; Smith CJ; Di Napoli M;
J Stroke Cerebrovasc Dis; 2018 Jan; 27(1):246-256. PubMed ID: 28935502
[TBL] [Abstract][Full Text] [Related]
18. Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease.
Tsukamoto Y; Takizawa S; Takahashi W; Mase H; Miyachi H; Miyata T; Takagi S
J Stroke Cerebrovasc Dis; 2011; 20(2):111-6. PubMed ID: 20580255
[TBL] [Abstract][Full Text] [Related]
19. High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.
Hsu PJ; Chen CH; Yeh SJ; Tsai LK; Tang SC; Jeng JS
Cerebrovasc Dis; 2016; 42(1-2):117-21. PubMed ID: 27088493
[TBL] [Abstract][Full Text] [Related]
20. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
